ICAM1 and Insulin resistance: The reduction of NF-κB activation by GW0742 treatment may account for the observed reduction in the serum levels of IL-6, which is known to be mostly released from skeletal muscle, and in the local expression of the NF-κB-dependent proteins iNOS and ICAM-1, whose role in the development of insulin resistance has been recently documented [38, 39].